De Novo nonalcoholic fatty liver disease after liver transplantation

Liver Transplantation

Volumn 13, Issue 6, 2007, Pages 788-790

  Abdelmalek, Manal F ^a   Diehl, Anna Mae ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; LIVER ENZYME; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RAPAMYCIN;

CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; EDITORIAL; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PREDICTION; PRIORITY JOURNAL; RECEPTOR BLOCKING; RISK FACTOR; WEIGHT GAIN;

FATTY LIVER; HUMANS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 34250622860     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21103     Document Type: Editorial

References (13)

1. Seo S, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C, et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007;13: 844-847.
2. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999;94:2467-2474.
3. Wang AY, Hickman IJ, Richards AA, Whitehead JP, Prins JB, Macdonald GA. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol 2005;100:2717-2723.
4. T D Correia MI, Rego LO, Lima AS. Post-liver transplant obesity and diabetes. Curr Opin Clin Nutr Metab Care 2003;6:457-460.
5. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64:2537-2565.
6. Hsieh PS. Reversal of fructose-induced hypertension and insulin resistance by chronic losartan treatment is independent of AT2 receptor activation in rats. J Hypertens 2005;23:2209-2217.
7. Kouyama R, Suganami T, Nishida J, Tanaka M, Toyoda T, Kiso M, et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005; 146:3481-3489.
8. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 2006;48:51-57.
9. Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. Int J Biochem Cell Biol 2006;38:766-781.
10. Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H, et al. The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, 1-amino acid-defined diet. Hepatol Res 2005;32:235-242.
11. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003:38:1008-1017.
12. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40: 820-826.
13. Angulo, P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999;30:1356-1362.